Holen Sie sich die Stockscreener-App
0.91
7.54%
-0.0742
Handel nachbörslich:
1.08
0.17
+18.68%
Schlusskurs vom Vortag:
$0.9842
Offen:
$0.91
24-Stunden-Volumen:
262.87K
Relative Volume:
1.60
Marktkapitalisierung:
$64.84M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-86.08M
KGV:
-0.4218
EPS:
-2.1574
Netto-Cashflow:
$-72.06M
1W Leistung:
-16.51%
1M Leistung:
+1.11%
6M Leistung:
-14.95%
1J Leistung:
-42.41%
1-Tages-Spanne:
$0.85
$0.96
1-Wochen-Bereich:
$0.85
$1.12
52-Wochen-Spanne:
$0.66
$1.79
Io Biotech Inc Stock (IOBT) Company Profile
Firmenname
Io Biotech Inc
Sektor
Branche
Telefon
(457) 070-2980
Adresse
OLE MAALOES VEH 3, COPENHAGEN
Vergleichen Sie IOBT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IOBT
Io Biotech Inc
|
0.91 | 64.84M | 0 | -86.08M | -72.06M | -2.1574 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 32.85B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 28.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Io Biotech Inc Aktie (IOBT) Neueste Nachrichten
Q1 Earnings Forecast for IO Biotech Issued By HC Wainwright - Defense World
Globus Medical acquires Nevro Corp. - Medical Buyer
Top 5 CRISPR Companies To Invest In (April 2025) - Securities.io
IO Biotech (NASDAQ:IOBT) Given “Buy” Rating at HC Wainwright - Defense World
IO Biotech secures over 400 million dkk in new capital - Dansk Industri
IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting - The Manila Times
IO Biotech Announces Acceptance Of Abstracts To Be Presented At The 2025 American Association For Cancer Research (AACR) Annual Meeting - MarketScreener
Cancer Vaccine Breakthrough: IO Biotech Reveals Phase 3 Melanoma Data at AACR 2025 - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - The Globe and Mail
Why Five Below Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket - Benzinga
IO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025 - The Manila Times
IO Biotech Named Among Fast Company’s World’s Most Innovative Companies of 2025 - TradingView
Fast Company Names IO Biotech Top 10 Innovator for Cancer Vaccine Breakthrough - StockTitan
These 10 biotech companies are changing how we discover new drugs and treat complex diseases - Fast Company
Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab - The Manila Times
Partex and Fortress Biotech Announce Strategic - GlobeNewswire
IO Biotech (NASDAQ:IOBT) Upgraded at Piper Sandler - Defense World
Cancer Vaccines Market Analysis: Growth Drivers - openPR.com
Bavarian Nordic A/S – Notice Convening Annual General Meeting - Finansavisen
HC Wainwright Reiterates “Buy” Rating for IO Biotech (NASDAQ:IOBT) - Defense World
Promising Clinical Developments and Delayed Data Boost IO Biotech’s Buy Rating - TipRanks
Best Biotech Stocks to Buy in 2025 - The Motley Fool
Ratio Chart Of U.S. Dollar Index Against 10Y U.S. Notes Is Pointing Much Lower - The Globe and Mail
Melanoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Melanoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, - openPR
BJ's (BJ) Q4 Earnings: What To Expect - The Globe and Mail
Dollar Retreats on Growth Risk From US Tariffs - The Globe and Mail
Metastatic Melanoma Pipeline 2024: Key Companies, MOA, ROA, - openPR
IOBT To Report Melanoma Trial Data In Q3, NPCE Eyes 15-20% Revenue Growth For 2025, DXR On Watch - RTTNews
IO Biotech on track with cancer vaccine BLA for 2025 By Investing.com - Investing.com Canada
IO Biotech on track with cancer vaccine BLA for 2025 - Investing.com India
IO Biotech Reports 2024 Business Highlights - The Manila Times
IO Biotech Reports Progress on Cylembio® Development and Upcoming FDA Submission Plans - Nasdaq
Cancer Vaccine Breakthrough? IO Biotech Accelerates Path to FDA Approval with Early Trial Completion - StockTitan
Zoom Stock: Leading the Video Market After Skype’s Exit - The Globe and Mail
The Search for the Next Keytruda: Immuno-Oncology’s Next Play - BioSpace
5 Best Biotech Stocks To Watch (March 2025) - Securities.io
IO Biotech (IOBT) to Release Quarterly Earnings on Tuesday - Defense World
United States Steel: Buy, Sell, or Hold? - The Globe and Mail
Pre-market Movers: BTAI, VRPX, DCGO, NBY... - RTTNews
Metastatic Melanoma Clinical Trials and Pipeline 2025: EMA, - openPR
Pre-market Movers: ISPC, TH, IVVD, TOVX... - RTTNews
Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025 - GlobeNewswire
Artivion (AORT) Q4 Earnings: What To Expect - The Globe and Mail
Should You Buy IonQ Stock Before Feb. 26? - The Globe and Mail
IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference - The Manila Times
IO Biotech Announces Positive Findings on TGF-β-Directed Peptide Vaccine for Solid Tumors at AACR-IO Conference - Nasdaq
Can This New Cancer Vaccine Outsmart Tumors? IO Biotech's Breakthrough Approach - StockTitan
32,667 Shares in IO Biotech, Inc. (NASDAQ:IOBT) Purchased by Vontobel Holding Ltd. - Defense World
3 Reasons to Avoid SGH and 1 Stock to Buy Instead - The Globe and Mail
Finanzdaten der Io Biotech Inc-Aktie (IOBT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):